Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Biofabrication, the most common co-covered peer. We currently track 1 Biotech story that mention Placenta-on-chip, all published on July 5, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Placenta-on-chip
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Biofabrication, the most common co-covered peer. We currently track 1 Biotech story that mention Placenta-on-chip, all published on July 5, 2026. Each carries 5 original sources on average.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Placenta-on-chip. Shared-story counts are live from our verified record — not editorial picks.
Indian researchers have developed a placenta-on-chip that replicates four key maternal-fetal barrier functions—hormone production, glucose transport, urea clearance, and selective permeability—offering pharma a scalable tool for drug safety screening. The device’s response to hyperglycemic conditions mimics gestational diabetes, and its design using conventional well plates enables wide adoption across pharmaceutical R&D labs, potentially cutting costs and accelerating regulatory-required fetal toxicity assessments.
Placenta-on-chip is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
